AVTX · Avalo Therapeutics, Inc.
← all insidersPharmaceutical Preparations · Listed on Nasdaq
Open-market insider flow over 30d · 90d · 180d · 365d · filter in table · CSV · JSON
Open-market trades10
Distinct insiders3
Bought$0
Sold$1.69M
Net flow$-1.69M
Recent filings
How to read this
- Filed
- Date the Form 4 was filed with the SEC. Insiders must file within 2 business days of the trade.
- Ticker
- The issuer's stock symbol. Select it to open that company's insider-activity page.
- Issuer
- The company whose shares were traded.
- Sector
- The issuer's industry (SEC SIC classification). Select a value to filter to that sector.
- Insider
- The reporting person: an officer, director, or 10% owner. Select a name to see all of their trades.
- Role
- The insider's relationship to the company: director, officer, or 10% owner.
- Code
- SEC transaction code describing the kind of transaction. Full official definitions are under “Transaction codes” below. A dot marks an open-market trade (P/S), the highest-conviction signal.
- Side
- Direction of the trade, from the filing's Acquired (A) ▲ / Disposed of (D) ▼ field: a buy or a sell.
- 10b5-1
- Trade made under a pre-arranged Rule 10b5-1 plan: scheduled in advance, not a discretionary decision (generally lower signal).
- Shares
- Number of shares in this transaction.
- Price
- Reported price per share. Blank for grants, gifts, and other trades with no stated price.
- Value
- Transaction value = shares × price. Left blank for grants, option exercises, gifts, and conversions, which have no cash price (see Own Δ for their impact).
- Owned after
- Form 4 column “Amount of Securities Beneficially Owned Following Reported Transaction(s)”: shares the insider held (directly or indirectly) immediately after this trade.
- Own Δ
- How much this trade changed the insider's own holding versus what they held just before it (not a share of the company). +45% grew it by 45%, 2.0× more than doubled it, −100% sold the entire stake, “new” built a position from nothing.
- Co. Δ
- Change in the insider's stake as a share of the whole company from this trade (transaction shares ÷ shares outstanding). The “(now …)” figure is their resulting total stake. Based on the latest reported shares outstanding; blank when unavailable.
- D/I
- Form 4 column “Ownership Form: Direct (D) or Indirect (I)”. Indirect holdings (for example, through a trust, fund, or family member) are detailed in the filing's “Nature of Indirect Beneficial Ownership.”
- Lag
- Days from the trade date to the filing date (Form 4 is due within 2 business days).
Transaction codes
Verbatim from the SEC's General Instructions for Forms 3, 4 and 5.
- P
- Open market or private purchase of non-derivative or derivative security
- S
- Open market or private sale of non-derivative or derivative security
- A
- Grant, award or other acquisition pursuant to Rule 16b-3(d)
- D
- Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
- F
- Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
- M
- Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
- G
- Bona fide gift
- C
- Conversion of derivative security
- X
- Exercise of in-the-money or at-the-money derivative security
- J
- Other acquisition or disposition (describe transaction)
| Filed ↓Date the Form 4 was filed with the SEC (due within 2 business days of the trade). | Insider | Role | CodeSEC transaction code describing the kind of transaction. See “How to read this” above for the official SEC definition of each code. The dot marks an open-market trade (P/S). | SideDirection of the trade: a buy (acquired ▲) or a sell (disposed ▼). | Shares | PriceReported price per share. Blank for trades with no stated price. | ValueTransaction value = shares × price. Left blank for grants, option exercises, gifts, and conversions, which have no cash price (see Own Δ). | Owned afterShares the insider held (directly or indirectly) immediately after this trade. | Own ΔHow much this trade changed the insider's own holding versus what they held just before it (not a share of the company). +45% grew it by 45%, 2.0× more than doubled it, −100% sold the entire stake, “new” built a position from nothing. | Co. ΔChange in the insider's stake as a share of the whole company from this trade (transaction shares ÷ shares outstanding). The “(now …)” figure is their resulting total stake in the company. Based on the latest reported shares outstanding; blank when unavailable. | Link to SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-01 | Doyle Mittie | Officer (Chief Medical Officer) | M | ▼ sell10b5-1 | 679→ 679 Common Stock | — | — | 113,734 | — | — | filing |
| 2026-09-01 | Doyle Mittie | Officer (Chief Medical Officer) | S | ▼ sell10b5-1 | 6790 | $20.00 | $13.6K | 51,776 | −1% | −<0.01% (now 0.10%) | filing |
| 2026-09-01 | Doyle Mittie | Officer (Chief Medical Officer) | M | ▲ buy10b5-1 | 6790 | $8.04 | $5.5K | 52,455 | +1% | +<0.01% (now 0.10%) | filing |
| 2026-08-19 | Doyle Mittie | Officer (Chief Medical Officer) | M | ▼ sell10b5-1 | 1,000→ 1,000 Common Stock | — | — | 123,750 | — | — | filing |
| 2026-08-19 | Doyle Mittie | Officer (Chief Medical Officer) | S | ▼ sell10b5-1 | 1,0000 | $20.00 | $20.0K | 51,776 | −2% | −<0.01% (now 0.10%) | filing |
| 2026-08-19 | Doyle Mittie | Officer (Chief Medical Officer) | M | ▲ buy10b5-1 | 1,0000 | $12.65 | $12.7K | 52,776 | +2% | +<0.01% (now 0.10%) | filing |
| 2026-08-19 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | M | ▼ sell10b5-1 | 31,031→ 31,031 Common Stock | — | — | 96,242 | — | — | filing |
| 2026-08-19 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | M | ▼ sell10b5-1 | 2,876→ 2,876 Common Stock | — | — | 127,273 | — | — | filing |
| 2026-08-19 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | M | ▼ sell10b5-1 | 37,945→ 37,945 Common Stock | — | — | 130,149 | — | — | filing |
| 2026-08-19 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | S | ▼ sell10b5-1 | 31,0310 | $20.05 | $622.3K | 39,900 | −44% | −0.06% (now 0.07%) | filing |
| 2026-08-19 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | M | ▲ buy10b5-1 | 31,0310 | $9.88 | $306.6K | 70,931 | +78% | +0.06% (now 0.13%) | filing |
| 2026-08-19 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | S | ▼ sell10b5-1 | 3,7490 | $19.94 | $74.8K | 39,900 | −9% | −<0.01% (now 0.07%) | filing |
| 2026-08-19 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | S | ▼ sell10b5-1 | 37,9450 | $19.85 | $753.3K | 43,649 | −47% | −0.07% (now 0.08%) | filing |
| 2026-08-19 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | M | ▲ buy10b5-1 | 2,8760 | $9.88 | $28.4K | 81,594 | +4% | +<0.01% (now 0.15%) | filing |
| 2026-08-19 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | M | ▲ buy10b5-1 | 37,9450 | $9.88 | $374.9K | 78,718 | +93% | +0.07% (now 0.15%) | filing |
| 2026-08-12 | Riley Jennifer | Officer (Chief Strategy Officer) | S | ▼ sell | 2,6550 | $19.59 | $52.0K | 37,041 | −7% | −<0.01% (now 0.07%) | filing |
| 2026-08-12 | Doyle Mittie | Officer (Chief Medical Officer) | M | ▼ sell10b5-1 | 679→ 679 Common Stock | — | — | 114,413 | — | — | filing |
| 2026-08-12 | Doyle Mittie | Officer (Chief Medical Officer) | S | ▼ sell10b5-1 | 6790 | $20.00 | $13.6K | 51,776 | −1% | −<0.01% (now 0.10%) | filing |
| 2026-08-12 | Doyle Mittie | Officer (Chief Medical Officer) | M | ▲ buy10b5-1 | 6790 | $8.04 | $5.5K | 52,455 | +1% | +<0.01% (now 0.10%) | filing |
| 2026-07-29 | Doyle Mittie | Officer (Chief Medical Officer) | M | ▼ sell10b5-1 | 1,000→ 1,000 Common Stock | — | — | 124,750 | — | — | filing |
| 2026-07-29 | Doyle Mittie | Officer (Chief Medical Officer) | S | ▼ sell10b5-1 | 1,0000 | $20.00 | $20.0K | 51,776 | −2% | −<0.01% (now 0.10%) | filing |
| 2026-07-29 | Doyle Mittie | Officer (Chief Medical Officer) | M | ▲ buy10b5-1 | 1,0000 | $12.65 | $12.7K | 52,776 | +2% | +<0.01% (now 0.10%) | filing |
| 2026-07-02 | Philip Ron M | Director | A | ▲ buy | 69→ 69 Common Stock | $15.04 | $1.0K | 69 | — | — | filing |
| 2026-07-02 | Doyle Mittie | Officer (Chief Medical Officer) | M | ▼ sell10b5-1 | 1,779→ 1,779 Common Stock | — | — | 115,092 | — | — | filing |
| 2026-07-02 | Doyle Mittie | Officer (Chief Medical Officer) | M | ▼ sell10b5-1 | 2,875→ 2,875 Common Stock | — | — | 125,750 | — | — | filing |
| 2026-07-02 | Doyle Mittie | Officer (Chief Medical Officer) | S | ▼ sell10b5-1 | 4,6540 | $20.00 | $93.1K | 51,776 | −8% | −<0.01% (now 0.10%) | filing |
| 2026-07-02 | Doyle Mittie | Officer (Chief Medical Officer) | M | ▲ buy10b5-1 | 1,7790 | $8.04 | $14.3K | 56,430 | +3% | +<0.01% (now 0.11%) | filing |
| 2026-07-02 | Doyle Mittie | Officer (Chief Medical Officer) | M | ▲ buy10b5-1 | 2,8750 | $12.65 | $36.4K | 54,651 | +6% | +<0.01% (now 0.10%) | filing |
| 2026-07-02 | Jain Rita | Director | A | ▲ buy | 1,080→ 1,080 Common Stock | $15.04 | $16.2K | 1,080 | — | — | filing |
| 2026-07-02 | Lind Kevin Robert | Director | A | ▲ buy | 1,105→ 1,105 Common Stock | $15.04 | $16.6K | 1,105 | — | — | filing |
| 2026-06-25 | Philip Ron M | Director | A | ▲ buy | 40,200→ 40,200 Common Stock | — | — | 40,200 | — | — | filing |
| 2026-06-25 | Doyle Mittie | Officer (Chief Medical Officer) | M | ▼ sell10b5-1 | 1,450→ 1,450 Common Stock | — | — | 116,871 | — | — | filing |
| 2026-06-25 | Doyle Mittie | Officer (Chief Medical Officer) | S | ▼ sell10b5-1 | 1,4500 | $18.00 | $26.1K | 51,776 | −3% | −<0.01% (now 0.10%) | filing |
| 2026-06-25 | Doyle Mittie | Officer (Chief Medical Officer) | M | ▲ buy10b5-1 | 1,4500 | $8.04 | $11.7K | 53,226 | +3% | +<0.01% (now 0.10%) | filing |
| 2026-06-12 | Riley Jennifer | Officer (Chief Strategy Officer) | F | ▼ sell | 5880 | $13.10 | $7.7K | 39,696 | −1% | −<0.01% (now 0.07%) | filing |
| 2026-06-12 | Doyle Mittie | Officer (Chief Medical Officer) | F | ▼ sell | 1,0840 | $13.10 | $14.2K | 51,776 | −2% | −<0.01% (now 0.10%) | filing |
| 2026-06-12 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | F | ▼ sell | 1380 | $13.10 | $1.8K | 40,773 | −0.3% | −<0.01% (now 0.08%) | filing |
| 2026-06-12 | VARKI PAUL | Officer (Chief Legal Officer) | F | ▼ sell | 1,0810 | $13.10 | $14.2K | 32,576 | −3% | −<0.01% (now 0.06%) | filing |
| 2026-06-04 | Truex Samantha | Director | A | ▲ buy | 20,100→ 20,100 Common Stock | — | — | 20,100 | — | — | filing |
| 2026-06-04 | KANTOFF AARON | Director | A | ▲ buy | 20,100→ 20,100 Common Stock | — | — | 20,100 | — | — | filing |
| 2026-06-04 | Jain Rita | Director | A | ▲ buy | 20,100→ 20,100 Common Stock | — | — | 20,100 | — | — | filing |
| 2026-06-04 | Lind Kevin Robert | Director | A | ▲ buy | 20,100→ 20,100 Common Stock | — | — | 20,100 | — | — | filing |
| 2026-06-04 | Heffernan Michael Thomas | Director | A | ▲ buy | 29,500→ 29,500 Common Stock | — | — | 29,500 | — | — | filing |
| 2026-06-04 | KAPLAN GILLA | Director | A | ▲ buy | 20,100→ 20,100 Common Stock | — | — | 20,100 | — | — | filing |
| 2026-06-01 | Doyle Mittie | Officer (Chief Medical Officer) | M | ▼ sell10b5-1 | 679→ 679 Common Stock | — | — | 118,321 | — | — | filing |
| 2026-06-01 | Doyle Mittie | Officer (Chief Medical Officer) | S | ▼ sell10b5-1 | 6790 | $16.00 | $10.9K | 47,122 | −1% | −<0.01% (now 0.09%) | filing |
| 2026-06-01 | Doyle Mittie | Officer (Chief Medical Officer) | M | ▲ buy10b5-1 | 6790 | $8.04 | $5.5K | 47,801 | +1% | +<0.01% (now 0.09%) | filing |
| 2026-05-26 | Riley Jennifer | Officer (Chief Strategy Officer) | A | ▲ buy | 34,2000 | — | — | 36,855 | 14× | +0.06% (now 0.07%) | filing |
| 2026-05-26 | Doyle Mittie | Officer (Chief Medical Officer) | A | ▲ buy | 43,5000 | — | — | 47,122 | 13× | +0.08% (now 0.09%) | filing |
| 2026-05-26 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | A | ▲ buy | 39,9000 | — | — | 40,323 | 95× | +0.07% (now 0.08%) | filing |
| 2026-05-26 | VARKI PAUL | Officer (Chief Legal Officer) | A | ▲ buy | 24,3000 | — | — | 27,934 | 7.7× | +0.05% (now 0.05%) | filing |
| 2026-05-26 | NEIL GARRY ARTHUR | Director, Officer (Chief Executive Officer) | A | ▲ buy | 100,2000 | — | — | 190,314 | 2.1× | +0.19% (now 0.35%) | filing |
| 2026-05-19 | Doyle Mittie | Officer (Chief Medical Officer) | M | ▼ sell10b5-1 | 3,000→ 3,000 Common Stock | — | — | 128,625 | — | — | filing |
| 2026-05-19 | Doyle Mittie | Officer (Chief Medical Officer) | S | ▼ sell10b5-1 | 3,0000 | $18.76 | $56.3K | 3,622 | −45% | −<0.01% (now <0.01%) | filing |
| 2026-05-19 | Doyle Mittie | Officer (Chief Medical Officer) | M | ▲ buy10b5-1 | 3,0000 | $12.65 | $38.0K | 6,622 | +83% | +<0.01% (now 0.01%) | filing |
| 2026-05-11 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | M | ▼ sell10b5-1 | 18,606→ 18,606 Common Stock | — | — | 168,094 | — | — | filing |
| 2026-05-11 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | S | ▼ sell10b5-1 | 18,6060 | $24.12 | $448.8K | 423 | −98% | −0.03% (now <0.01%) | filing |
| 2026-05-11 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | M | ▲ buy10b5-1 | 18,6060 | $9.88 | $183.8K | 19,029 | 45× | +0.03% (now 0.04%) | filing |
| 2026-05-07 | Doyle Mittie | Officer (Chief Medical Officer) | M | ▼ sell10b5-1 | 28,650→ 28,650 Common Stock | — | — | 119,000 | — | — | filing |
| 2026-05-07 | Doyle Mittie | Officer (Chief Medical Officer) | M | ▼ sell10b5-1 | 77,905→ 77,905 Common Stock | — | — | 131,625 | — | — | filing |
| 2026-05-07 | Doyle Mittie | Officer (Chief Medical Officer) | M | ▼ sell10b5-1 | 679→ 679 Common Stock | — | — | 147,650 | — | — | filing |
| 2026-05-07 | Doyle Mittie | Officer (Chief Medical Officer) | M | ▼ sell10b5-1 | 1,000→ 1,000 Common Stock | — | — | 209,530 | — | — | filing |
| 2026-05-07 | Doyle Mittie | Officer (Chief Medical Officer) | S | ▼ sell10b5-1 | 10,0580 | $22.88 | $230.1K | 3,622 | −74% | −0.02% (now <0.01%) | filing |
| 2026-05-07 | Doyle Mittie | Officer (Chief Medical Officer) | S | ▼ sell10b5-1 | 19,0150 | $22.41 | $426.1K | 13,680 | −58% | −0.04% (now 0.03%) | filing |
| 2026-05-07 | Doyle Mittie | Officer (Chief Medical Officer) | S | ▼ sell10b5-1 | 44,9440 | $21.20 | $952.7K | 32,695 | −58% | −0.08% (now 0.06%) | filing |
| 2026-05-07 | Doyle Mittie | Officer (Chief Medical Officer) | S | ▼ sell10b5-1 | 5,0000 | $19.65 | $98.3K | 77,639 | −6% | −<0.01% (now 0.14%) | filing |
| 2026-05-07 | Doyle Mittie | Officer (Chief Medical Officer) | S | ▼ sell10b5-1 | 27,5380 | $18.03 | $496.4K | 82,639 | −25% | −0.05% (now 0.15%) | filing |
| 2026-05-07 | Doyle Mittie | Officer (Chief Medical Officer) | M | ▲ buy10b5-1 | 28,6500 | $8.04 | $230.3K | 110,177 | +35% | +0.05% (now 0.21%) | filing |
| 2026-05-07 | Doyle Mittie | Officer (Chief Medical Officer) | M | ▲ buy10b5-1 | 77,9050 | $12.65 | $985.5K | 81,527 | 23× | +0.15% (now 0.15%) | filing |
| 2026-05-07 | Doyle Mittie | Officer (Chief Medical Officer) | S | ▼ sell10b5-1 | 1,6790 | $16.00 | $26.9K | 3,622 | −32% | −<0.01% (now <0.01%) | filing |
| 2026-05-07 | Doyle Mittie | Officer (Chief Medical Officer) | M | ▲ buy10b5-1 | 6790 | $8.04 | $5.5K | 5,301 | +15% | +<0.01% (now <0.01%) | filing |
| 2026-05-07 | Doyle Mittie | Officer (Chief Medical Officer) | M | ▲ buy10b5-1 | 1,0000 | $12.65 | $12.7K | 4,622 | +28% | +<0.01% (now <0.01%) | filing |
| 2026-05-07 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | M | ▼ sell10b5-1 | 47,000→ 47,000 Common Stock | — | — | 116,000 | — | — | filing |
| 2026-05-07 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | S | ▼ sell10b5-1 | 8,9000 | $22.57 | $200.9K | 423 | −95% | −0.02% (now <0.01%) | filing |
| 2026-05-07 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | S | ▼ sell10b5-1 | 9,2190 | $21.37 | $197.0K | 9,323 | −50% | −0.02% (now 0.02%) | filing |
| 2026-05-07 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | S | ▼ sell10b5-1 | 2,7000 | $20.76 | $56.1K | 18,542 | −13% | −<0.01% (now 0.03%) | filing |
| 2026-05-07 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | S | ▼ sell10b5-1 | 12,3470 | $19.28 | $238.1K | 21,242 | −37% | −0.02% (now 0.04%) | filing |
| 2026-05-07 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | S | ▼ sell10b5-1 | 13,8340 | $18.55 | $256.7K | 33,589 | −29% | −0.03% (now 0.06%) | filing |
| 2026-05-07 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | M | ▲ buy10b5-1 | 47,0000 | $8.04 | $377.9K | 47,423 | 112× | +0.09% (now 0.09%) | filing |
| 2026-05-07 | Chan Mitchell | Director | S | ▼ sell10b5-1 | 3,1670 | $22.88 | $72.5K | 3,166 | −50% | −<0.01% (now <0.01%) | filing |
| 2026-05-07 | VARKI PAUL | Officer (Chief Legal Officer) | M | ▼ sell10b5-1 | 12,563→ 12,563 Common Stock | — | — | 87,437 | — | — | filing |
| 2026-05-07 | VARKI PAUL | Officer (Chief Legal Officer) | M | ▼ sell10b5-1 | 62,500→ 62,500 Common Stock | — | — | 87,500 | — | — | filing |
| 2026-05-07 | VARKI PAUL | Officer (Chief Legal Officer) | S | ▼ sell10b5-1 | 4000 | $23.71 | $9.5K | 3,634 | −10% | −<0.01% (now <0.01%) | filing |
| 2026-05-07 | VARKI PAUL | Officer (Chief Legal Officer) | S | ▼ sell10b5-1 | 9,2530 | $22.70 | $210.0K | 4,034 | −70% | −0.02% (now <0.01%) | filing |
| 2026-05-07 | VARKI PAUL | Officer (Chief Legal Officer) | S | ▼ sell10b5-1 | 22,8390 | $21.22 | $484.5K | 13,287 | −63% | −0.04% (now 0.02%) | filing |
| 2026-05-07 | VARKI PAUL | Officer (Chief Legal Officer) | S | ▼ sell10b5-1 | 5,1960 | $19.78 | $102.8K | 36,126 | −13% | −<0.01% (now 0.07%) | filing |
| 2026-05-07 | VARKI PAUL | Officer (Chief Legal Officer) | S | ▼ sell10b5-1 | 37,3750 | $18.91 | $706.8K | 41,322 | −47% | −0.07% (now 0.08%) | filing |
| 2026-05-07 | VARKI PAUL | Officer (Chief Legal Officer) | M | ▲ buy10b5-1 | 12,5630 | $8.04 | $101.0K | 78,697 | +19% | +0.02% (now 0.15%) | filing |
| 2026-05-07 | VARKI PAUL | Officer (Chief Legal Officer) | M | ▲ buy10b5-1 | 62,5000 | $13.43 | $839.4K | 66,134 | 18× | +0.12% (now 0.12%) | filing |
| 2026-05-01 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | S | ▼ sell10b5-1 | 8,4570 | $13.23 | $111.9K | 423 | −95% | −0.02% (now <0.01%) | filing |
| 2026-05-01 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | S | ▼ sell10b5-1 | 8,4580 | $13.09 | $110.7K | 8,880 | −49% | −0.02% (now 0.02%) | filing |
| 2026-04-08 | Doyle Mittie | Officer (Chief Medical Officer) | M | ▼ sell10b5-1 | 3,970→ 3,970 Common Stock | — | — | 210,530 | — | — | filing |
| 2026-04-08 | Doyle Mittie | Officer (Chief Medical Officer) | S | ▼ sell10b5-1 | 3,9700 | $18.01 | $71.5K | 3,622 | −52% | −<0.01% (now <0.01%) | filing |
| 2026-04-08 | Doyle Mittie | Officer (Chief Medical Officer) | M | ▲ buy10b5-1 | 3,9700 | $12.65 | $50.2K | 7,592 | 2.1× | +<0.01% (now 0.01%) | filing |
| 2026-04-03 | Doyle Mittie | Officer (Chief Medical Officer) | M | ▼ sell10b5-1 | 679→ 679 Common Stock | — | — | 148,329 | — | — | filing |
| 2026-04-03 | Doyle Mittie | Officer (Chief Medical Officer) | S | ▼ sell10b5-1 | 6790 | $16.00 | $10.9K | 3,622 | −16% | −<0.01% (now <0.01%) | filing |
| 2026-04-03 | Doyle Mittie | Officer (Chief Medical Officer) | M | ▲ buy10b5-1 | 6790 | $8.04 | $5.5K | 4,301 | +19% | +<0.01% (now <0.01%) | filing |
| 2026-04-03 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | S | ▼ sell10b5-1 | 1,7800 | $17.57 | $31.3K | 17,338 | −9% | −<0.01% (now 0.03%) | filing |
| 2026-04-03 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | S | ▼ sell10b5-1 | 6,2000 | $17.02 | $105.6K | 19,118 | −24% | −0.01% (now 0.04%) | filing |
| 2026-04-03 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | S | ▼ sell10b5-1 | 7,4790 | $16.83 | $125.8K | 25,318 | −23% | −0.01% (now 0.05%) | filing |
| 2026-04-03 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | S | ▼ sell10b5-1 | 5000 | $15.86 | $7.9K | 32,797 | −2% | −<0.01% (now 0.06%) | filing |
| 2026-04-01 | Jain Rita | Director | A | ▲ buy | 1,339→ 1,339 Common Stock | $12.13 | $16.2K | 1,339 | — | — | filing |
| 2026-04-01 | Lind Kevin Robert | Director | A | ▲ buy | 1,370→ 1,370 Common Stock | $12.13 | $16.6K | 1,370 | — | — | filing |
| 2026-03-31 | Truex Samantha | Director | M | ▼ sell | 3,166→ 3,166 Common Stock | — | — | 3,167 | — | — | filing |
| 2026-03-31 | Truex Samantha | Director | M | ▲ buy | 3,1660 | — | — | 6,333 | +100% | +<0.01% (now 0.01%) | filing |
| 2026-03-31 | Goldman Jonathan | Director | M | ▼ sell | 3,166→ 3,166 Common Stock | — | — | 3,167 | — | — | filing |
| 2026-03-31 | Goldman Jonathan | Director | M | ▲ buy | 3,1660 | — | — | 3,166 | new | +<0.01% (now <0.01%) | filing |
| 2026-03-31 | KANTOFF AARON | Director | M | ▼ sell | 3,166→ 3,166 Common Stock | — | — | 3,167 | — | — | filing |
| 2026-03-31 | KANTOFF AARON | Director | M | ▲ buy | 3,1660 | — | — | 6,333 | +100% | +<0.01% (now 0.01%) | filing |
| 2026-03-31 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | M | ▼ sell | 24,200→ 24,200 Common Stock | — | — | 24,200 | — | — | filing |
| 2026-03-31 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | F | ▼ sell | 8,2410 | $13.89 | $114.5K | 33,297 | −20% | −0.02% (now 0.06%) | filing |
| 2026-03-31 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | M | ▲ buy | 24,2000 | — | — | 41,538 | 2.4× | +0.05% (now 0.08%) | filing |
| 2026-03-31 | Chan Mitchell | Director | M | ▼ sell | 3,166→ 3,166 Common Stock | — | — | 3,167 | — | — | filing |
| 2026-03-31 | Chan Mitchell | Director | M | ▲ buy | 3,1660 | — | — | 6,333 | +100% | +<0.01% (now 0.01%) | filing |
| 2026-03-31 | NEIL GARRY ARTHUR | Director, Officer (Chief Executive Officer) | M | ▼ sell | 64,866→ 64,866 Common Stock | — | — | 64,867 | — | — | filing |
| 2026-03-31 | NEIL GARRY ARTHUR | Director, Officer (Chief Executive Officer) | F | ▼ sell | 21,8920 | $13.89 | $304.1K | 90,114 | −20% | −0.04% (now 0.17%) | filing |
| 2026-03-31 | NEIL GARRY ARTHUR | Director, Officer (Chief Executive Officer) | M | ▲ buy | 64,8660 | — | — | 112,006 | 2.4× | +0.12% (now 0.21%) | filing |
| 2026-03-31 | KAPLAN GILLA | Director | M | ▼ sell | 3,166→ 3,166 Common Stock | — | — | 3,167 | — | — | filing |
| 2026-03-31 | KAPLAN GILLA | Director | M | ▲ buy | 3,1660 | — | — | 6,333 | +100% | +<0.01% (now 0.01%) | filing |
Up to 200 most recent filings · select a heading to sort, or open “How to read this” above for definitions · this company on SEC EDGAR.